NY-JAMESTOWN
16.12.2021 22:57:14 CET | Business Wire | Press release
The world’s biggest New Year’s Eve party is returning to the metaverse this year with the relaunch of VNYE , an immersive virtual experience set in the epicenter of New Year's Eve: Times Square. Through the VNYE app and website, people from across the globe can explore the virtual world of Times Square, play games, and livestream New Year’s Eve celebrations in Times Square and around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006118/en/
Jamestown , the owner of One Times Square, which is the site of the New Year’s Eve Ball Drop Celebration, launched VNYE last year as a new way to celebrate New Year’s Eve amid the pandemic and cancellation of in-person celebrations. In total, VNYE reached more than 3.7 million people worldwide in 2021.
“We created VNYE to amplify the New Year’s Eve experience and keep the world connected to Times Square when physical access was limited,” said Michael Phillips, President of Jamestown. “In its second iteration, VNYE will both complement the return of in-person celebrations and serve as a destination in its own right—an immersive virtual world where people from across the globe can gather to celebrate the New Year.”
“Times Square New Year’s Eve is a global celebration that connects the world as we collectively say goodbye to the year past and look with hope to the year ahead,” said Tom Harris, President of the Times Square Alliance. “Jamestown has deepened those connections through this innovative VNYE technology allowing people from around the globe to interact with Times Square and this iconic celebration in ways that we never imagined.”
In the VNYE metaverse, users can create personalized avatars, explore the Times Square Plazas, collect confetti to earn points for additional avatar customizations, and visit the observation deck at One Times Square to view the virtual world of Times Square from above.
Inside One Times Square, users can discover three unique and immersive games: Dance World, where users show off their dance skills; Nature World, where users can take in various nature landscapes and engage in a scavenger hunt to collect pieces of the iconic New Year’s Eve Ball; and Zero G, where users can travel around the globe through a slide experience, visiting an array of the world’s landmarks while earning power-ups and points along the way.
Starting December 31, 2021, users can choose from 11 live camera feeds in Times Square and seven EarthCam live streams of New Year’s Eve celebrations from around the globe, including in Rio de Janeiro, Brazil, and Budapest, Hungary.
At midnight on New Year’s Eve, users can ring in the new year in the Times Square metaverse with a virtual Ball Drop Celebration and fireworks show.
The VNYE app will be available to download in app stores starting December 18, 2021, with livestreams starting December 31, 2021. For more information, visit VNYE.com and follow along at @onetimessquarenyc.
About Jamestown
Jamestown is a global, design-focused real estate investment and management firm with a 38-year track record and mission to create places that inspire. Since its founding in 1983, Jamestown has executed transactions in excess of $35 billion. As of September 30, 2021, Jamestown has assets under management of $13.1 billion and a portfolio spanning key markets throughout the U.S., Latin America, and Europe. Jamestown employs more than 400 people worldwide with headquarters in Atlanta and Cologne, and offices in Amsterdam, Bogotá, Boston, London, Los Angeles, Madrid, Milan, New York, San Francisco, and Washington, D.C. Current and previous projects include One Times Square and Chelsea Market in New York, Industry City in Brooklyn, Ponce City Market in Atlanta, Ghirardelli Square in San Francisco, the Innovation and Design Building in Boston, and Groot Handelsgebouw in Rotterdam. For more information, visit www.jamestownlp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006118/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
